Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A SetbackInvestors Business Daily • 11/28/22
Axsome's stock rallies 15% on promising findings for its experimental Alzheimer's drugMarket Watch • 11/28/22
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer's Disease AgitationGlobeNewsWire • 11/28/22
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/23/22
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.The Motley Fool • 11/18/22
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/07/22
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022GlobeNewsWire • 10/21/22